FDA inspection delays for key biosimilars
Approvals for Aspart and Bevacizumab are delayed due to FDA's inability to inspect sites, with no clear timeline for resolution, potentially impacting revenue growth and margin expansion.
BIOCON / Q3-FY24 / risks
Keep the risk register visible.
Biocon · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Pricing pressure in generics API business
Generics API business faces intense pricing competition from Chinese and Indian suppliers, leading to a 7% YoY revenue decline and uncertainty in near-term recovery.
High net debt and interest rate exposure
BBL net debt stands at $1.2B (excluding structured instruments), with floating-rate SOFR-linked debt exposing the company to high interest costs, which could pressure cash flows and R&D investment.
Adalimumab market opening slower than expected
The U.S. Adalimumab biosimilar market is expected to open meaningfully only in CY2025, delaying potential revenue contribution from this large opportunity.